Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

Xingxing Zang, Peggy S. Sullivan, Robert A. Soslow, Rebecca Waitz, Victor E. Reuter, Andrew Wilton, Howard T. Thaler, Manonmani Arul, Susan F. Slovin, Joyce Wei, David R. Spriggs, Jakob Dupont, James P. Allison

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

B7-H3 and B7x are members of the B7 family of immune regulatory ligands that are thought to attenuate peripheral immune responses through co-inhibition. Previous studies have correlated their overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. We sought to examine the expression of B7-H3 and B7x in 103 ovarian borderline tumors and carcinomas and study associations with clinical outcome. Using immunohistochemical tissue microarray analysis on tumor specimens, we found that 93 and 100% of these ovarian tumors express B7-H3 and B7x, respectively, with expression found predominantly on cell membranes and in cytoplasm. In contrast, only scattered B7-H3-and B7x-positive cells were detected in non-neoplastic ovarian tissues. B7-H3 was also expressed in the endothelium of tumor-associated vasculature in 44% of patients, including 78% of patients with high-stage tumors (FIGO stages III and IV), nearly all of which were high-grade serous carcinomas, and 26% of patients with low-stage tumors (FIGO stages I and II; P0.001), including borderline tumors. Analysis of cumulative survival time and recurrence incidence revealed that carcinomas with B7-H3-positive tumor vasculature were associated with a significantly shorter survival time (P0.02) and a higher incidence of recurrence (P0.03). The association between B7-H3-positive tumor vasculature and poor clinical outcome remained significant even when the analysis was limited to the high-stage subgroup. These results show that ovarian borderline tumors and carcinomas aberrantly express B7-H3 and B7x, and that B7-H3-positive tumor vasculature is associated with high-grade serous histological subtype, increased recurrence and reduced survival. B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas.

Original languageEnglish (US)
Pages (from-to)1104-1112
Number of pages9
JournalModern Pathology
Volume23
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Carcinoma
Survival
Neoplasms
Recurrence
Tissue Array Analysis
Endometrioid Carcinoma
Tumor-Infiltrating Lymphocytes
Incidence
Survival Analysis
Ovarian Neoplasms
Endothelium
Cytoplasm
Cell Membrane
Ligands

Keywords

  • B7
  • co-inhibition
  • co-stimulation
  • endothelium
  • ovarian cancer
  • serous carcinoma
  • T cell
  • tumor vasculature

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Zang, X., Sullivan, P. S., Soslow, R. A., Waitz, R., Reuter, V. E., Wilton, A., ... Allison, J. P. (2010). Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern Pathology, 23(8), 1104-1112. https://doi.org/10.1038/modpathol.2010.95

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. / Zang, Xingxing; Sullivan, Peggy S.; Soslow, Robert A.; Waitz, Rebecca; Reuter, Victor E.; Wilton, Andrew; Thaler, Howard T.; Arul, Manonmani; Slovin, Susan F.; Wei, Joyce; Spriggs, David R.; Dupont, Jakob; Allison, James P.

In: Modern Pathology, Vol. 23, No. 8, 08.2010, p. 1104-1112.

Research output: Contribution to journalArticle

Zang, X, Sullivan, PS, Soslow, RA, Waitz, R, Reuter, VE, Wilton, A, Thaler, HT, Arul, M, Slovin, SF, Wei, J, Spriggs, DR, Dupont, J & Allison, JP 2010, 'Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas', Modern Pathology, vol. 23, no. 8, pp. 1104-1112. https://doi.org/10.1038/modpathol.2010.95
Zang, Xingxing ; Sullivan, Peggy S. ; Soslow, Robert A. ; Waitz, Rebecca ; Reuter, Victor E. ; Wilton, Andrew ; Thaler, Howard T. ; Arul, Manonmani ; Slovin, Susan F. ; Wei, Joyce ; Spriggs, David R. ; Dupont, Jakob ; Allison, James P. / Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. In: Modern Pathology. 2010 ; Vol. 23, No. 8. pp. 1104-1112.
@article{f55c8c065bb144018a2954d3a3691cf2,
title = "Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas",
abstract = "B7-H3 and B7x are members of the B7 family of immune regulatory ligands that are thought to attenuate peripheral immune responses through co-inhibition. Previous studies have correlated their overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. We sought to examine the expression of B7-H3 and B7x in 103 ovarian borderline tumors and carcinomas and study associations with clinical outcome. Using immunohistochemical tissue microarray analysis on tumor specimens, we found that 93 and 100{\%} of these ovarian tumors express B7-H3 and B7x, respectively, with expression found predominantly on cell membranes and in cytoplasm. In contrast, only scattered B7-H3-and B7x-positive cells were detected in non-neoplastic ovarian tissues. B7-H3 was also expressed in the endothelium of tumor-associated vasculature in 44{\%} of patients, including 78{\%} of patients with high-stage tumors (FIGO stages III and IV), nearly all of which were high-grade serous carcinomas, and 26{\%} of patients with low-stage tumors (FIGO stages I and II; P0.001), including borderline tumors. Analysis of cumulative survival time and recurrence incidence revealed that carcinomas with B7-H3-positive tumor vasculature were associated with a significantly shorter survival time (P0.02) and a higher incidence of recurrence (P0.03). The association between B7-H3-positive tumor vasculature and poor clinical outcome remained significant even when the analysis was limited to the high-stage subgroup. These results show that ovarian borderline tumors and carcinomas aberrantly express B7-H3 and B7x, and that B7-H3-positive tumor vasculature is associated with high-grade serous histological subtype, increased recurrence and reduced survival. B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas.",
keywords = "B7, co-inhibition, co-stimulation, endothelium, ovarian cancer, serous carcinoma, T cell, tumor vasculature",
author = "Xingxing Zang and Sullivan, {Peggy S.} and Soslow, {Robert A.} and Rebecca Waitz and Reuter, {Victor E.} and Andrew Wilton and Thaler, {Howard T.} and Manonmani Arul and Slovin, {Susan F.} and Joyce Wei and Spriggs, {David R.} and Jakob Dupont and Allison, {James P.}",
year = "2010",
month = "8",
doi = "10.1038/modpathol.2010.95",
language = "English (US)",
volume = "23",
pages = "1104--1112",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

AU - Zang, Xingxing

AU - Sullivan, Peggy S.

AU - Soslow, Robert A.

AU - Waitz, Rebecca

AU - Reuter, Victor E.

AU - Wilton, Andrew

AU - Thaler, Howard T.

AU - Arul, Manonmani

AU - Slovin, Susan F.

AU - Wei, Joyce

AU - Spriggs, David R.

AU - Dupont, Jakob

AU - Allison, James P.

PY - 2010/8

Y1 - 2010/8

N2 - B7-H3 and B7x are members of the B7 family of immune regulatory ligands that are thought to attenuate peripheral immune responses through co-inhibition. Previous studies have correlated their overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. We sought to examine the expression of B7-H3 and B7x in 103 ovarian borderline tumors and carcinomas and study associations with clinical outcome. Using immunohistochemical tissue microarray analysis on tumor specimens, we found that 93 and 100% of these ovarian tumors express B7-H3 and B7x, respectively, with expression found predominantly on cell membranes and in cytoplasm. In contrast, only scattered B7-H3-and B7x-positive cells were detected in non-neoplastic ovarian tissues. B7-H3 was also expressed in the endothelium of tumor-associated vasculature in 44% of patients, including 78% of patients with high-stage tumors (FIGO stages III and IV), nearly all of which were high-grade serous carcinomas, and 26% of patients with low-stage tumors (FIGO stages I and II; P0.001), including borderline tumors. Analysis of cumulative survival time and recurrence incidence revealed that carcinomas with B7-H3-positive tumor vasculature were associated with a significantly shorter survival time (P0.02) and a higher incidence of recurrence (P0.03). The association between B7-H3-positive tumor vasculature and poor clinical outcome remained significant even when the analysis was limited to the high-stage subgroup. These results show that ovarian borderline tumors and carcinomas aberrantly express B7-H3 and B7x, and that B7-H3-positive tumor vasculature is associated with high-grade serous histological subtype, increased recurrence and reduced survival. B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas.

AB - B7-H3 and B7x are members of the B7 family of immune regulatory ligands that are thought to attenuate peripheral immune responses through co-inhibition. Previous studies have correlated their overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. We sought to examine the expression of B7-H3 and B7x in 103 ovarian borderline tumors and carcinomas and study associations with clinical outcome. Using immunohistochemical tissue microarray analysis on tumor specimens, we found that 93 and 100% of these ovarian tumors express B7-H3 and B7x, respectively, with expression found predominantly on cell membranes and in cytoplasm. In contrast, only scattered B7-H3-and B7x-positive cells were detected in non-neoplastic ovarian tissues. B7-H3 was also expressed in the endothelium of tumor-associated vasculature in 44% of patients, including 78% of patients with high-stage tumors (FIGO stages III and IV), nearly all of which were high-grade serous carcinomas, and 26% of patients with low-stage tumors (FIGO stages I and II; P0.001), including borderline tumors. Analysis of cumulative survival time and recurrence incidence revealed that carcinomas with B7-H3-positive tumor vasculature were associated with a significantly shorter survival time (P0.02) and a higher incidence of recurrence (P0.03). The association between B7-H3-positive tumor vasculature and poor clinical outcome remained significant even when the analysis was limited to the high-stage subgroup. These results show that ovarian borderline tumors and carcinomas aberrantly express B7-H3 and B7x, and that B7-H3-positive tumor vasculature is associated with high-grade serous histological subtype, increased recurrence and reduced survival. B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas.

KW - B7

KW - co-inhibition

KW - co-stimulation

KW - endothelium

KW - ovarian cancer

KW - serous carcinoma

KW - T cell

KW - tumor vasculature

UR - http://www.scopus.com/inward/record.url?scp=77955172320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955172320&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2010.95

DO - 10.1038/modpathol.2010.95

M3 - Article

C2 - 20495537

AN - SCOPUS:77955172320

VL - 23

SP - 1104

EP - 1112

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 8

ER -